Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

XNK Therapeutics continues platform development work with AdBIOPRO after Sweden’s Vinnova extends investment

XNK Therapeutics AB (“XNK”) today said the company would continue its partnership with the Karolinska Cell Therapy Center’s production unit Vecura under the lead of Pontus Blomberg and Veronique Chotteau’s group in Cell Technology from the Swedish Royal Institute of Technology as part of a collaboration within The Competence Centre for Advanced BioProduction by Continuous Processing, AdBIOPRO.“The Swedish government-sponsored innovation agency Vinnova has granted AdBIOPRO competence center an extension of five years. This means we can continue our part of the collaboration within AdBIOPRO

Repurchase of Truecaller B shares in week 46, 2022

During 14 November 2022 and 18 November 2022 Truecaller AB (publ) (LEI code 549300TEYF1FA5G5GK26) has repurchased in total 437,837 own B shares (ISIN: SE0016787071) as part of the share buyback programme initiated by the board of directors.The share buybacks form part of the share buyback programme announced by Truecaller on 23 September 2022. The share buyback programme will be executed between 23 September and up until the 2023 AGM, is being carried out in accordance “Emittentregelverket”.   Truecaller B shares have been repurchased as follows: Date: Aggregated daily

IBS – an undertreated condition

With a prevalence of 11 per cent, IBS is considered one of the world’s most common conditions. Although innocuous, it significantly impacts the sufferer’s quality of life and leads to high societal costs. Today, there is no effective pharmacological treatment for IBS, but research is still ongoing to solve the riddle and achieve a breakthrough. BioStock takes a closer look at the condition.Read the full article at biostock.se :https://www.biostock.se/en/2022/11/ibs-an-undertreated-condition/This is a press release from BioStock – Connecting Innovation &

Kebni releases new strategic plan for 2023-2027

SummaryKebni is a Swedish tech company well-positioned in a growing market powered by the global mega-trends “space”, “automation” and “connectivity”. With it’s unique mix of Inertial Sensing and SatCom skills, Kebni develops advanced technological solutions for stabilisation, positioning, safety and satellite communication. In it’s strategic plan for 2023-2027, the company’s objective is to reach a net revenue of 150-200 MSEK in 2024 and 20-25% annual growth the following years. Kebni also sets out to reach positive cashflow and an EBITDA-margin of 5-10% in financial year 2024. To reach

Webstep ASA: Share purchase programme for employees

Oslo, 21 November 2022: The board of directors of Webstep ASA (the "Company") has resolved to implement a share purchase programme for employees in the Company and its subsidiary Webstep AS who reside in Norway (the "Share Purchase Programme"), on the basis of the authorisation granted to the board of directors by the extraordinary general meeting of the Company on 23 November 2021 (the "Authorisation").The participants in the Share Purchase Programme will be offered to acquire new shares in the Company for an amount of between NOK 5,000 and NOK 24,000 each (the "Offer").  The

Lagercrantz has resolved to evaluate a potential sale of up to 1.5 million repurchased B-shares

The board of directors of Lagercrantz Group AB (publ) (”Lagercrantz”) has, in accordance with the authorization from the annual general meeting held 30 August 2022, resolved to evaluate a potential sale of up to 1.5 million repurchased B-shares held by the company at market value, corresponding to up to approximately 0.7 percent of the total number of outstanding shares and up to approximately 0.5 percent of the number of votes in Lagercrantz.Danske Bank A/S, Denmark, Sweden Branch (”Danske Bank”) has been instructed to explore the possibility to sell the B-shares and the share price and

Notice of the extraordinary general meeting in Cint Group AB (publ)

The shareholders of Cint Group AB (publ) (“Cint” or the “Company”) are hereby given notice of an extraordinary general meeting to be held on 14 December 2022 at 10:00 CET at Convendum, Conference 1, Biblioteksgatan 29, SE-114 35 Stockholm. The entrance to the meeting will open at 09:30 CET. The board of directors has decided, pursuant to the Company’s articles of association, that shareholders shall also have the right to exercise their voting rights by postal voting. Shareholders may therefore choose to exercise their voting rights at the general meeting by attending in person, through

PHI IS OPENING A NEW DEVELOPMENT OFFICE IN THE US

As a result of the newly created alliance for advancing cell-based biomanufacturing  which was recently communicated, Phase Holographic Imaging (PHI) is taking the next step in its investment into regenerative medicine by opening an office in the Innovation Quarter  in Winston-Salem.The new office is in, what is called, the Regenerative Medicine Hub (RegenMed Hub™), where PHI will develop its non-invasive technology for cell quality control

Atlas Copco completes acquisition of a US based cryostat manufacturer

Nacka, Sweden, 21 Nov 2022: Atlas Copco has completed the acquisition of Montana Instruments Corporation, which was announced in August. The company provides cryostat solutions for customers involved in physics research and low temperature technology solutions.Montana Instruments Corporation is a privately owned company with 38 employees, located in Bozeman, Montana, USA. In 2021, the company had revenues of approximately MUSD 12 (MSEK 106*). The purchase price is not disclosed. The company will become part of the Scientific Vacuum division within the Vacuum Technique Business Area.

Interim Financial Report – first nine months of 2022 (Q3 2022)

21 November Company2022                                                               announcement no. 60 Today, SGL International A/S has published its Interim Financial Report for the first nine months of 2022 (Q3 2022). SGL Group (SGL International A/S) · For SGL Group, the Q3 2022 revenue was DKK 4,419m versus DKK 2,641m in Q3 2021; an increase of 67%, primarily driven higher activity levels and larger share of wallet with both new and existing

Medivir recruits Pia Baumann as new Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Pia Baumann has been recruited as its new Chief Medical Officer (CMO). Her role includes overall responsibility for the continued clinical development of the candidate drug fostroxacitabine bralpamide (fostrox). She will be part of the company's management team and will take up her position on February 20, 2023. Pia Baumann, who is an MD specialized in oncology and earned her Ph.D. at Karolinska

Nomination Committee RugVista Group AB (publ) appointed

The Nomination Committee of RugVista Group AB (publ) (“RugVista”) has been formed in accordance with the company’s “Instruction for the Nomination Committee” as adopted by the Annual General Meeting. The Nomination Committee appointed for RugVista’s 2023 Annual General Meeting has the following composition: · Gunnar Mattsson (representative of madHat AB, and chairperson of the Nomination Committee) · Klara Hanzon (representative of TIN Ny Teknik) · Erik Lindgren (chairperson of RugVista’s Board of Directors) Shareholders who wish to submit proposals to the Nomination Committee

BioStock: Pricing in focus for Respiratorius ahead of partnering discussions

Oncology company Respiratorius are now working on marketing VAL001 with the aim of securing a partnership. A new formulation and the possibility of differentiation from already available products is considered the single most important component to ensure attractive pricing for an upcoming market launch. In this article, BioStock looks at the company’s own pricing analysis and the market potential that it believes the project possesses.Read the full article at biostock.se: https://www.biostock.se/en/2022/11/pricing-in-focus-for-respiratorius-ahead-of-partnering-discussions/ This is a

Nordhealth AS - Invitation to Q3 2022 presentation

Nordhealth will report and present its Q3 2022 results on Friday the 25th of November 2022.The results will be presented in a live presentation and subsequent Q&A session with CEO Charles MacBain and CFO Mari Orttenvuori on the 25th of November at 13:00 CET. Please use the following link to attend: https://us02web.zoom.us/j/82134750106 The presentation will be recorded and made available on www.nordhealth.com. The presentation material for Q3 will be available on 25 November 2022 at 07:30 am CET on www.newsweb.no and on Nordhealth's IR website https://nordhealth.com/investor/news-and-

Idogen’s scientific adviser Jan Holgersson strengthens the company’s Board of Directors

Idogen AB (publ) announced today that Jan Holgersson, who has served for several years as scientific adviser to the company, has agreed to strengthen the company’s Board of Directors in the role as co-opted Board member.   Jan Holgersson is a professor of Transplant Immunology at Gothenburg University, the Medical Director of the Tissue Typing and Stem Cell Laboratories at Sahlgrenska University Hospital in Gothenburg, where he was also formerly the Head of Clinical Immunology and Transfusion Medicine. His research focuses on understanding the immunological mechanisms that underlie

Nordic Nanovector comment on Proposed Merger with APIM Therapeutics

Oslo, Norway, 21 November 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") desires to share more information with the Company’s shareholders about the proposed merger between the Company and APIM Therapeutics (“APIM”). The Company has scheduled a webcast, including a question and answers session, on Thursday, November 24 at 4.30 CET. Practical details regarding the webcast will be issued in a separate notice. Any questions may be submitted to ir@nordicnanovector.com. The Board of Nordic Nanovector and its advisors reiterates its belief that the merger

Genetic Analysis AS announces the outcome of the warrant exercise

Oslo, Norway, November 21, 2022 – On November 16, 2022, the exercise period for Genetic Analysis AS's ("GA" or the "Company") warrants of series TO 1, issued in connection with the Company's IPO of units in September/October 2021, ended. No warrants of series TO 1 have been exercised. The reason for this is deemed to be that the subscription price for the exercise of warrants of series TO 1 has exceeded the current share price during the entire exercise period.During the period November 2 until November 16, 2022, holders of warrants of series TO 1 were, for each warrant, entitled to

Kindred challenges the coercive fine in Norway

Kindred Group, via its wholly owned Maltese subsidiary Trannel International Ltd, has been informed that the Norwegian Gaming Authority has decided to reinstate the coercive fine against Trannel International despite the changes Kindred Group has undertaken. Kindred Group disagrees with the legal basis for the non-enforceable fine and will continue to challenge this in the courts.Kindred Group plc (Kindred) has during the past month, via its wholly owned Maltese subsidiary Trannel International Ltd (Trannel), performed several changes in its offering to ensure compliance with the

Results from lecanemab confirmatory phase 3 Clarity AD study to be presented at 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference

Stockholm, November 21, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the efficacy, safety and biomarker results from the Phase 3 confirmatory Clarity AD clinical trial for lecanemab[1] (development code: BAN2401), at the 15[th] Clinical Trials on Alzheimer’s Disease (CTAD) conference, held in San Francisco, CA and virtually from November 29 to December 2. The data will be presented by Eisai and distinguished faculty members in a scientific session on the first day of the meeting (November 29 at 4:50 p.m. PT). Additionally, BioArctic will present a poster

Africa Oil announces results of share buyback program

November 21, 2022 (AOI–TSX, AOI–Nasdaq-Stockholm) – Africa Oil Corp. (“Africa Oil”, or the “Company”) is pleased to announce that the Company repurchased a total of 1,667,480 Africa Oil common shares during the period of November 14, 2022 to November 18, 2022 under the previously announced share buyback program. View PDF version  The launch of Africa Oil’s normal course issuer bid (share buyback) program, announced by the Company on September 22, 2022, is being implemented in accordance with the Market Abuse Regulation (EU)

First Camp considers issuance of sustainability linked bonds and announces conditional tender offer and notice of early redemption for the outstanding 2019/2023 bonds

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) (THE "SECURITIES ACT") OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS (IN PARTICULAR,

Research: urban residents want to invest in the development of public transport, cycling and walking

YIT Corporation Press release 21 November 2022 at 9:00 a.m.According to a barometer commissioned by YIT, when asked about the three main modes of transport that urban residents would like to see investment in, the most important in cities are public transport (50% of respondents), cycling (47%) and walking (45%).  The importance of good public transport connections and cycle paths has continued to increase in the appreciation of one’s own residential area from 47% in 2021 to 58% in 2022. Their importance is highlighted in Helsinki, Tampere, Turku, Oulu and Jyväskylä.  Residents want

Mycronic receives order for an SLX mask writer

Mycronic AB (publ) has received an order for an SLX mask writer from a new customer in Asia. The order value is in the range of USD 4-6 million. Delivery of the system is planned for the fourth quarter of 2023.The SLX laser mask writer meets rising demand for photomasks for the semiconductor industry and a future need for replacement and modernization. Photomasks manufactured by laser mask writers are of high importance and account for 70-75 percent of all photomasks produced for semiconductor manufacturing. SLX is a modern and energy efficient mask writer based on the same technology as

There are no items matching the current filter
There are no more items matching the current filter
Back to top